Anti-Coagulants - Central Asia

Central Asia

The Anti-Coagulants market in Central Asia is expected to achieve a revenue of US$36.25m by 2024.
It is projected to experience a steady annual growth rate (CAGR 2024-2029) of 8.71%, leading to a market volume of US$55.03m by 2029.
Among all countries, United States will contribute the highest revenue, amounting to US$16,740.00m in 2024.
In Central Asia, the demand for anti-coagulants is rising steadily, driven by an aging population and increasing awareness about the importance of cardiovascular health.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Coagulants in Central Asia has been steadily increasing in recent years.

Customer preferences: The rise in the geriatric population and the increasing prevalence of cardiovascular diseases have led to an increase in demand for anti-coagulants in Central Asia. Patients prefer anti-coagulants as they are more effective in preventing blood clots and reducing the risk of stroke.

Trends in the market: Kazakhstan is the largest market for anti-coagulants in Central Asia, followed by Uzbekistan and Kyrgyzstan. The demand for anti-coagulants in Kazakhstan is driven by the increasing incidence of cardiovascular diseases and the growing geriatric population. In Uzbekistan, the demand for anti-coagulants is driven by the high prevalence of thrombosis, while in Kyrgyzstan, the demand is driven by the increasing incidence of stroke.

Local special circumstances: Central Asia is a region that is still developing and has a high burden of disease. The healthcare systems in these countries are not well developed, and access to healthcare is limited in some areas. This has led to a rise in the prevalence of chronic diseases such as cardiovascular diseases. The lack of access to healthcare has also resulted in a lack of awareness about the importance of preventive measures such as regular health check-ups and lifestyle modifications.

Underlying macroeconomic factors: The economic growth in Central Asia has been steady in recent years, with a focus on diversification and modernization of the economy. However, the healthcare sector has not received the same level of investment as other sectors. This has led to a shortage of healthcare professionals and a lack of modern medical equipment. The governments in Central Asia are now focusing on improving the healthcare sector, which is expected to drive the demand for anti-coagulants in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.